Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | PKM | P14618 | 3/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3481223 | 0.90 | PRKCI (0.39) | NPC1RAB9APKMCYP2A6MIF | |
| SCHEMBL3481461 | 0.88 | BACE1 (0.38) | NPC1RAB9APKMCYP2A6HTR2C | |
| SCHEMBL13113458 | 0.86 | PRKCI (0.43) | NPC1RAB9APKMCYP2A6CRBN | |
| SCHEMBL13113450 | 0.86 | NPC1 (0.47) | NPC1RAB9APKMCYP2A6HTR2C | |
| SCHEMBL13871874 | 0.85 | CYP2A6 (0.34) | CYP2A6MIFLPAR5 | |
| SCHEMBL13113424 | 0.85 | HTR2C (0.48) | NPC1RAB9APKMCYP2A6HTR2C | |
| SCHEMBL13113370 | 0.84 | NPC1 (0.56) | NPC1RAB9APKMCYP2A6HTR2C | |
| SCHEMBL13113108 | 0.83 | MEN1 (0.46) | NPC1RAB9APKMCYP2A6HTR2C | |
| SCHEMBL13113721 | 0.83 | HTR6 (0.46) | NPC1RAB9APKMHTR2CSMN1; SMN2 | |
| SCHEMBL13113714 | 0.83 | HTR7 (0.37) | NPC1RAB9APKMCYP2A6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as represented by the Secretary, Department of Health and | 2010-10-21 | — | — | US | disclosed |
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as represented by the Secretary, Department of Health and | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267712-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | SMN1; SMN2, SYNCRIP, RNMT | NPC1 1441/4885RAB9A 985/4885PKM 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.